Stocktoria
TENAX THERAPEUTICS, INC. TENX
TENAX THERAPEUTICS, INC. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | — | — | — | — | — | — | — | $0 |
| Gross profit | — | — | — | — | — | — | — | — | — | $0 |
| R&D expense | $32.7M | $12.7M | $3.2M | $5.4M | $25.1M | $4.6M | $3.5M | $1.2M | $3.5M | $13.1M |
| SG&A expense | — | — | — | — | $7.6M | $5.3M | $5.1M | $5.7M | $5.7M | $6.2M |
| Operating income | -$56.4M | -$19.5M | -$8.2M | $11.1M | -$32.7M | $9.9M | -$8.6M | -$6.9M | -$9.2M | -$52.7M |
| Interest expense | $0 | $23,000 | $24,000 | $4,443 | $949 | $1,627 | $0 | — | — | $0 |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | -$8.0M |
| Net income | -$52.6M | -$17.6M | -$7.7M | $11.0M | -$32.5M | -$9.9M | -$8.4M | -$14.1M | -$8.8M | -$43.9M |
| EPS (diluted) | $-1.34 | $-1.15 | $-31.04 | — | — | — | — | — | — | — |
| Operating cash flow | -$35.8M | -$14.8M | -$5.9M | -$11.4M | -$10.9M | -$9.3M | -$7.6M | -$5.5M | -$12.1M | -$15.9M |
| Free cash flow | — | — | — | -$11.4M | -$10.9M | -$9.3M | -$7.6M | -$5.5M | -$12.1M | -$15.9M |
| Cash & equivalents | $97.6M | $94.9M | $9.8M | $2.1M | $5.6M | $6.3M | $4.9M | $12.4M | $1.6M | $10.0M |
| Total assets | $104.2M | $96.7M | $11.7M | $3.4M | $6.0M | $6.9M | $6.4M | $13.3M | $9.9M | $23.3M |
| Total liabilities | $7.2M | $4.7M | $3.6M | $1.9M | $1.7M | $2.2M | $2.6M | $1.6M | $1.0M | $6.2M |
| Shareholders' equity | $97.1M | $92.0M | $8.1M | $1.5M | $4.2M | $4.6M | $3.8M | $11.8M | $8.9M | $17.1M |
Growth · year-over-year
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income growth | — | — | -169.8% | — | — | — | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.